Significant regression of left ventricular hypertrophy in patient with arterial hypertension during antihypertensive treatment with perindopril and atorvastatin

Left ventricular hypertrophy (LVH) in arterial hypertension (AH) is one of the modifiable risk factors for cardiovascular events and serves as a justified goal for antihypertensive therapy. The article presents follow-up of a 60-year-old female with AH, hyperlipidemia, and discovered of LVH on the data of electrocardiography and echocardiography. In addition to the SokolowLyon and Cornell voltage criteria, the baseline echocardiographic examination revealed and increase in thickness of the ventricular septum and the left ventricular (LV) posterior wall, an increase in LV myocardial mass and LV myocardial mass index. The patient was recommended to take a drug of the class of angiotensin converting enzyme inhibitors perindopril and atorvastatin. The patient regularly received therapy and periodically underwent repeated echocardiographic examinations. After 40 months follow-up there are a significant decrease in septal hypertrophy (from 1.22 to 0.76 cm, -37.7%), LV posterior wall (from 1.05 to 0.49, -53.3%), as well as LV myocardial mass (from 197.9 to 96 g, -51.5%) and LV myocardial mass index (from 111.18 to 59.11 g/ m2, -51.5%). Thus, during the entire period of follow-up, the LV mass decreased almost twice. There was a decrease in the size of the left atrium, the relative wall thickness, with the same parameters of LV volumes, characteristics of systolic and diastolic function. Among the favorable factors contributing to significant LVH regression, high adherence to treatment, the efficacy of angiotensin converting enzyme inhibitors and the possible antihypertrophic influence of atorvastatin are discussed.

1. Balanova YuA, Shalnova SA, Imaeva AE, Kapustina AV, Muromtseva GA, Evstifeeva SE et al. Prevalence, Awareness, Treatment and Control of Hypertension in Russian Federation (Data of Observational ESSE-RF-2 Study). Rational Pharmacotherapy in Cardiology. 2019;15(4):450–466. (In Russ.) https://doi.org/10.20996/1819-6446-2019-15-4-450-466.

2. Brouwers S, Sudano I, Kokubo Y, Sulaica EM. Arterial hypertension. Lancet. 2021;398(10296):249–261. https://doi.org/10.1016/S0140-6736(21)00221-X.

3. Nemtsova V, Vischer AS, Burkard T. Hypertensive heart disease: a narrative review series-part 1: pathophysiology and microstructural changes. J Clin Med. 2023;12(7):2606. https://doi.org/10.3390/jcm12072606.

4. Kobalava ZhD, Konradi AO, Nedogoda SV, Shlyakhto EV, Arutyunov GP, Baranova EI et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786. (In Russ.) https://doi.org/10.15829/1560-4071-2020-3-3786.

5. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398(10304):957–980. https://doi.org/10.1016/S0140-6736(21)01330-1.

6. Ismail TF, Frey S, Kaufmann BA, Winkel DJ, Boll DT, Zellweger MJ, Haaf P. Hypertensive heart disease-the imaging perspective. J Clin Med. 2023;12(9):3122. https://doi.org/10.3390/jcm12093122.

7. Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12):1874–2071. https://doi.org/10.1097/HJH.0000000000003480.

8. Brooks JE, Soliman EZ, Upadhya B. Is left ventricular hypertrophy a valid therapeutic target? Curr Hypertens Rep. 2019;21(6):47. https://doi.org/10.1007/s11906-019-0952-9.

9. Kim HM, Hwang I-C, Choi H-M, Yoon YE, Cho G-Y. Prognostic implication of left ventricular hypertrophy regression after antihypertensive therapy in patients with hypertension. Front Cardiovasc Med. 2022;9:1082008. https://doi.org/10.3389/fcvm.2022.1082008

10. Dai H, Bragazzi NL, Younis A, Zhong W, Liu X, Wu J et al. Worldwide trends in prevalence, mortality, and disability-adjusted life years for hypertensive heart disease from 1990 to 2017. Hypertension. 2021;77(4):1223–1233. https://doi.org/10.1161/HYPERTENSIONAHA.120.16483.

11. Bragazzi NL, Zhong W, Shu J, Abu Much A, Lotan D, Grupper A et al. Burden of heart failure and underlying causes in 195 countries and territories from 1990 to 2017. Eur J Prev Cardiol. 2021;28(15):1682–1690. https://doi.org/10.1093/eurjpc/zwaa147.

12. Drazner MH. The progression of hypertensive heart disease. Circulation. 2011;123(3):327–334. https://doi.org/10.1161/CIRCULATIONAHA.108.845792.

13. Bacharova L, Chevalier P, Gorenek B, Jons C, Li YG, Locati ET et al. ISE/ ISHNE Expert Consensus Statement on ECG diagnosis of left ventricular hypertrophy: the change of the paradigm. The joint paper of the International Society of Electrocardiology and the International Society for Holter Monitoring and Noninvasive Electrocardiology. J Electrocardiol. 2023;81:85–93. https://doi.org/10.1016/j.jelectrocard.2023.08.005.

14. Martin TG, Juarros MA, Leinwand LA. Regression of cardiac hypertrophy in health and disease: mechanisms and therapeutic potential. Nat Rev Cardiol. 2023;20(5):347–363. https://doi.org/10.1038/s41569-022-00806-6.

15. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1-39.e14. https://doi.org/10.1016/j.echo.2014.10.003.

16. Cokkinos DV. Cardiac hypertrophy. In: Cokkinos D (ed.). Myocardial Preservation. Springer, Cham; 2019. Chap. 5, pp. 63–86. https://doi.org/10.1007/978-3-319-98186-4_5.

17. Jekell A, Nilsson PM, Kahan T. Treatment of hypertensive left ventricular hypertrophy. Curr Pharm Des. 2018;24(37):4391–4396. https://doi.org/10.2174/1381612825666181203092918.

18. Nadruz W. Myocardial remodeling in hypertension. J Hum Hypertens. 2015;29(1):1–6. https://doi.org/10.1038/jhh.2014.36.

19. Cuspidi C, Sala C, Negri F, Mancia G, Morganti A; Italian Society of Hypertension. Prevalence of left-ventricular hypertrophy in hypertension: an updated review of echocardiographic studies. J Hum Hypertens. 2012;26(6):343–349. https://doi.org/10.1038/jhh.2011.104.

20. Chu HW, Hwang IC, Kim HM, Park J, Choi H, Choi HM et al. Age-dependent implications of left ventricular hypertrophy regression in patients with hypertension. Hypertens Res. 2024;47(5):1144–1156. https://doi.org/10.1038/s41440-023-01571-w.

21. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ ASPC/NMA/PCNA Guideline for the Prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71(19):e127-e248. https://doi.org/10.1016/j.jacc.2017.11.006.

22. de la Sierra A. New American and European hypertension guidelines, reconciling the differences. Cardiol Ther. 2019;8(2):157–166. https://doi.org/10.1007/s40119-019-0144-3.

23. Marwick TH, Gillebert TC, Aurigemma G, Chirinos J, Derumeaux G, Galderisi M et al. Recommendations on the use of echocardiography in adult hypertension: a report from the European Association of Cardiovascular Imaging (EACVI) and the American Society of Echocardiography (ASE)†. Eur Heart J Cardiovasc Imaging. 2015;16(6):577–605. https://doi.org/10.1093/ehjci/jev076.

24. Yildiz M, Oktay AA, Stewart MH, Milani RV, Ventura HO, Lavie CJ. Left ventricular hypertrophy and hypertension. Prog Cardiovasc Dis. 2020;63(1):10–21. https://doi.org/10.1016/j.pcad.2019.11.009.

25. Semenkin AA, Druk IV, Potapov VV, Sapronenko VS, Zakharova AV. Hypertensive heart: from left ventricular hypertrophy to chronic heart failure. Arterial Hypertension. 2023;29(2):138–149. (In Russ.) https://doi.org/10.18705/1607-419X-2023-29-2-138-149.

26. Cramariuc D, Gerdts E. Epidemiology of left ventricular hypertrophy in hypertension: implications for the clinic. Expert Rev Cardiovasc Ther. 2016;14(8):915–926. https://doi.org/10.1080/14779072.2016.1186542.

27. Milani RV, Drazner MH, Lavie CJ, Morin DP, Ventura HO. Progression from concentric left ventricular hypertrophy and normal ejection fraction to left ventricular dysfunction. Am J Cardiol. 2011;108(7):992–996. https://doi.org/10.1016/j.amjcard.2011.05.038.

28. Xu H, Hu B, Wu W, Jin Y. Comparative efficacy of different types of antihypertensive drugs in reversing left ventricular hypertrophy as determined with echocardiography in hypertensive patients: a protocol for systematic review and meta-analysis. Medicine (Baltimore). 2021;100(25):e26455. https://doi.org/10.1097/MD.0000000000026455.

29. Lønnebakken MT, Izzo R, Mancusi C, Gerdts E, Losi MA, Canciello G et al. Left ventricular hypertrophy regression during antihypertensive treatment in an outpatient clinic (the Campania Salute Network). J Am Heart Assoc. 2017;6(3):e004152. https://doi.org/10.1161/JAHA.116.004152.

30. Kwiecinski J, Lennen RJ, Gray GA, Borthwick G, Boswell L, Baker AH et al. Progression and regression of left ventricular hypertrophy and myocardial fibrosis in a mouse model of hypertension and concomitant cardiomyopathy. J Cardiovasc Magn Reson. 2020;22(1):57. https://doi.org/10.1186/s12968-020-00655-7.

31. Budzyń M, Gryszczyńka B, Boruczkowski M, Kaczmarek M, Begier-Krasińska B, Osińska A et al. The potential role of circulating endothelial cells and endothelial progenitor cells in the prediction of left ventricular hypertrophy in hypertensive patients. Front Physiol. 2019;10:1005. https://doi.org/10.3389/fphys.2019.01005.

32. Chen JS, Pei Y, Li CE, Li YN, Wang QY, Yu J. Comparative efficacy of different types of antihypertensive drugs in reversing left ventricular hypertrophy as determined with echocardiography in hypertensive patients: a network meta-analysis of randomized controlled trials. J Clin Hypertens (Greenwich). 2020;22(12):2175–2183. https://doi.org/10.1111/jch.14047.

33. Fagard RH, Celis H, Thijs L, Wouters S. Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies. Hypertension. 2009;54(5):1084–1091. https://doi.org/10.1161/HYPERTENSIONAHA.109.136655.

34. Soliman EZ, Prineas RJ. Antihypertensive therapies and left ventricular hypertrophy. Curr Hypertens Rep. 2017;19(10):79. https://doi.org/10.1007/s11906-017-0777-3.

35. Muiesan ML, Paini A, Bertacchini F, Rosei CA, Salvetti M. Regression under treatment of left ventricular hypertrophy and other structural alterations. In: Dorobantu M, Mancia G, Grassi G, Voicu V (eds.). Hypertension and Heart Failure. Updates in Hypertension and Cardiovascular Protection. Springer, Cham; 2019. https://doi.org/10.1007/978-3-319-93320-7_19.

36. Dyadyk AI, Bagriy AE, Lebed IA, Yarovaya NF, Schukina EV, Taradin GG. ACE inhibitors captopril and enalapril induce regression of left ventricular hypertrophy in hypertensive patients with chronic renal failure. Nephrol Dial Transplant. 1997;12(5):945–951. https://doi.org/10.1093/ndt/12.5.945.

37. Hanif K, Bid HK, Konwar R. Reinventing the ACE inhibitors: some old and new implications of ACE inhibition. Hypertens Res. 2010;33(1):11–21. https://doi.org/10.1038/hr.2009.184.

38. Ahmed SN, Jhaj R, Sadasivam B, Joshi R. Regression of the left ventricular hypertrophy in patients with essential hypertension on standard drug therapy. Discoveries (Craiova). 2020;8(3):e115. https://doi.org/10.15190/d.2020.12.

39. Tai C, Gan T, Zou L, Sun Y, Zhang Y, Chen W et al. Effect of angiotensinconverting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2017;17(1):257. https://doi.org/10.1186/s12872-017-0686-z.

40. Simko F. Statins: a perspective for left ventricular hypertrophy treatment. Eur J Clin Invest. 2007;37(9):681–691. https://doi.org/10.1111/j.1365-2362.2007.01837.x.

41. Ray S. Role of statins in the management of dyslipidaemia. Indian Heart J. 2024;76(Suppl. 1):S33–S37. https://doi.org/10.1016/j.ihj.2023.11.267.

42. Choudhary A, Rawat U, Kumar P, Mittal P. Pleotropic effects of statins: the dilemma of wider utilization of statin. Egypt Heart J. 2023;75(1):1. https://doi.org/10.1186/s43044-023-00327-8.

43. Khan Z, Gul A, Mlawa G, Bhattacharjee P, Muhammad SA, Carpio J et al. Statins as anti-hypertensive therapy: a systematic review and meta-analysis. Cureus. 2024;16(4):e57825. https://doi.org/10.7759/cureus.57825.

44. Ovchinnikov A, Belyavskiy E, Potekhina A, Ageev F. Asymptomatic left ventricular hypertrophy is a potent risk factor for the development of HFpEF but not HFrEF: results of a retrospective cohort study. J Clin Med. 2022;11(13):3885. https://doi.org/10.3390/jcm11133885.